Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00445692 · OUTCOME

Survival

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma · Source last updated 2019-11-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From date of transplant until the date of death from any cause, assessed up to 10.25 years

What was measured

number of patients alive or dead

Groups in this outcome

Treatment (Clarithromycin, Dexamethasone, Lenalidomide)

Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin. NOTE: \*After one year of treatment, dexamethasone is tapered for an additional 4 weeks. Clarithromycin: Given Orally (PO) Dexamethasone: Given PO Lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Clarithromycin, Dexamethasone, Lenalidomide)31

Reported measurements

Source class 1

Multiple meyloma deaths

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Clarithromycin, Dexamethasone, Lenalidomide)10Not reportedNot reportedNot reportedNot reported

Acute Myeloid Leukemia death

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Clarithromycin, Dexamethasone, Lenalidomide)1Not reportedNot reportedNot reportedNot reported

Lung cancer death

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Clarithromycin, Dexamethasone, Lenalidomide)1Not reportedNot reportedNot reportedNot reported

Heart attack death

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Clarithromycin, Dexamethasone, Lenalidomide)1Not reportedNot reportedNot reportedNot reported

Alive

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Clarithromycin, Dexamethasone, Lenalidomide)18Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
      title
      Multiple meyloma deaths
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      Acute Myeloid Leukemia death
    3. measurements
      1. group Id
        OG000
        value
        1
      title
      Lung cancer death
    4. measurements
      1. group Id
        OG000
        value
        1
      title
      Heart attack death
    5. measurements
      1. group Id
        OG000
        value
        18
      title
      Alive
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
number of patients alive or dead
groups
  1. description
    Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin. NOTE: \*After one year of treatment, dexamethasone is tapered for an additional 4 weeks. Clarithromycin: Given Orally (PO) Dexamethasone: Given PO Lenalidomide: Given PO
    id
    OG000
    title
    Treatment (Clarithromycin, Dexamethasone, Lenalidomide)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
From date of transplant until the date of death from any cause, assessed up to 10.25 years
title
Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice